Neumora Stock
HealthTechLooking to sell Neumora stock or options?
Eligible for:
Charitable Exchange Fund
Neumora Therapeutics Inc, a clinical-stage biopharmaceutical company, is addressing the brain disease crisis by adopting a fundamentally different approach to developing treatments. The company has expanded its therapeutic pipeline, which now includes seven clinical and preclinical neuroscience programs targeting novel mechanisms for a wide range of underserved neuropsychiatric and neurodegenerative disorders. Among its pipeline are NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. Ne
Investors Include:
SoftBank Investment Advisers, Gershon Capital, Amgen, Biomatics Capital, ARCH Venture Partners.